Skip to main content
Top
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer

Authors: Hendrik Dapper, Markus Oechsner, Stefan Münch, Kai Borm, Jan Peeken, Michael Mayinger, Stephanie E. Combs, Daniel Habermehl

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

The cranial border of the target volume (TV) in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT) is mostly defined at the level of L5/S1. However, current studies have shown that relapse cranially of the target volume after neoadjuvant nCRT and surgery is very rare. A reduction of cranial TV margins could be reasonable to reduce toxicity to the organs at risk (OAR). In this study we compared the dose distribution to the OAR for different cranial longitudinal margins using a dose-volume histogram (DVH) analysis.

Methods

Ten patients with loco regional advanced rectal cancer were analysed retrospectively. All patients were planned for Volumetric Arc Therapy Radiation Therapy (VMAT). Next to the original PTV (PTV0), three new planning target volumes (PTV) were defined for each patient: The PTV0 reduced by 1 cm, 2 cm and 3 cm on cranial extension. For each PTV a treatment plan with a total dose of 50.4 Gy with daily doses of 1.8 Gy was calculated. Dose to the OAR were evaluated and compared.

Results

For the bone marrow, the small bowel and the peritoneal space all clinically relevant relative dose parameters (V10-V50) as well as the Dmedian could be significantly reduced with every cranial target volume reduction of 1 cm. For V10 of the peritoneal space the dose could be nearly halved with a 3 cm shortened TV. After TV reduction of 3 cm also for the urinary bladder a significant dose reduction of the Dmedian could be achieved.

Conclusions

Considering the very low recurrence rates in the TME and IMRT era, the distribution patterns of these relapses as well as the relevant side effects of nCRT, we would agree with existing recommendations of reduction of the cranial target volume in nCRT treated rectal cancer patients.
Literature
1.
go back to reference S3-Leitlinie kolorektales Karzinom. Langversion 2.0 - November 2017 - AWMF-Registernummer: 021/007OL. Stuttgart: Thieme; 2017. S3-Leitlinie kolorektales Karzinom. Langversion 2.0 - November 2017 - AWMF-Registernummer: 021/007OL. Stuttgart: Thieme; 2017.
2.
go back to reference Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMed Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMed
3.
go back to reference Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008–15.CrossRefPubMed Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008–15.CrossRefPubMed
4.
go back to reference Peeters KCMJ, Marijnen CAM, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693–701.CrossRefPubMed Peeters KCMJ, Marijnen CAM, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693–701.CrossRefPubMed
5.
go back to reference Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894–9.CrossRefPubMed Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894–9.CrossRefPubMed
6.
go back to reference Enríquez-Navascués JM, Borda N, Lizerazu A, et al. Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol. 2011;17:1674–84.CrossRefPubMedPubMedCentral Enríquez-Navascués JM, Borda N, Lizerazu A, et al. Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol. 2011;17:1674–84.CrossRefPubMedPubMedCentral
7.
go back to reference Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and Para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51:261–6.CrossRefPubMed Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and Para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51:261–6.CrossRefPubMed
8.
go back to reference Mell LK, Tiryaki H, Ahn K-H, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:1504–10.CrossRefPubMed Mell LK, Tiryaki H, Ahn K-H, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:1504–10.CrossRefPubMed
9.
go back to reference Wee CW, Kang H-C, Wu H-G, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. Jpn J Clin Oncol. 2018;48:458–66.CrossRefPubMed Wee CW, Kang H-C, Wu H-G, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. Jpn J Clin Oncol. 2018;48:458–66.CrossRefPubMed
10.
go back to reference Mitra D, Hong TS, Horick N, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017;2:110–7.CrossRefPubMedPubMedCentral Mitra D, Hong TS, Horick N, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017;2:110–7.CrossRefPubMedPubMedCentral
11.
go back to reference Yang TJ, Oh JH, Apte A, Son CH, Deasy JO, Goodman KA. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiother Oncol. 2014;113:29–34.CrossRefPubMedPubMedCentral Yang TJ, Oh JH, Apte A, Son CH, Deasy JO, Goodman KA. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiother Oncol. 2014;113:29–34.CrossRefPubMedPubMedCentral
12.
go back to reference Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–65.CrossRefPubMed Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–65.CrossRefPubMed
13.
go back to reference Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys. 2008;72:658–64.CrossRefPubMed Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys. 2008;72:658–64.CrossRefPubMed
14.
go back to reference Nijkamp J, Kusters M, Beets-Tan RGH, et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys. 2011;80:103–10.CrossRefPubMed Nijkamp J, Kusters M, Beets-Tan RGH, et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys. 2011;80:103–10.CrossRefPubMed
15.
go back to reference Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824–30.CrossRefPubMed Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824–30.CrossRefPubMed
16.
go back to reference Valentini V, Gambacorta MA, Barbaro B, et al. International consensus guidelines on clinical target volume delineation in rectal cancer. Radiother Oncol. 2016;120:195–201.CrossRefPubMed Valentini V, Gambacorta MA, Barbaro B, et al. International consensus guidelines on clinical target volume delineation in rectal cancer. Radiother Oncol. 2016;120:195–201.CrossRefPubMed
17.
go back to reference Nijkamp J, Marijnen C, van Herk M, van Triest B, Sonke J-J. Adaptive radiotherapy for long course neo-adjuvant treatment of rectal cancer. Radiother Oncol. 2012;103:353–9.CrossRefPubMed Nijkamp J, Marijnen C, van Herk M, van Triest B, Sonke J-J. Adaptive radiotherapy for long course neo-adjuvant treatment of rectal cancer. Radiother Oncol. 2012;103:353–9.CrossRefPubMed
18.
go back to reference Banerjee R, Chakraborty S, Nygren I, Sinha R. Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques. Int J Radiat Oncol Biol Phys. 2013;85:1225–31.CrossRefPubMed Banerjee R, Chakraborty S, Nygren I, Sinha R. Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques. Int J Radiat Oncol Biol Phys. 2013;85:1225–31.CrossRefPubMed
19.
go back to reference Münch S, Oechsner M, Combs SE, Habermehl D. DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer. Radiat Oncol. 2017;12:128.CrossRefPubMedPubMedCentral Münch S, Oechsner M, Combs SE, Habermehl D. DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer. Radiat Oncol. 2017;12:128.CrossRefPubMedPubMedCentral
20.
go back to reference Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed
21.
go back to reference Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRefPubMed Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRefPubMed
22.
go back to reference Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1141–7.CrossRefPubMed Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1141–7.CrossRefPubMed
23.
go back to reference Ceelen W, Fierens K, van Nieuwenhove Y, Pattyn P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer. 2009;124:2966–72.CrossRefPubMed Ceelen W, Fierens K, van Nieuwenhove Y, Pattyn P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer. 2009;124:2966–72.CrossRefPubMed
24.
go back to reference Franco P, Arcadipane F, Ragona R, et al. Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. Expert Rev Anticancer Ther. 2017;17:335–45.CrossRefPubMed Franco P, Arcadipane F, Ragona R, et al. Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. Expert Rev Anticancer Ther. 2017;17:335–45.CrossRefPubMed
25.
go back to reference Cheng JC-H, Bazan JG, Wu J-K, Koong AC, Chang DT. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Pract Radiat Oncol. 2014;4:198–206.CrossRefPubMed Cheng JC-H, Bazan JG, Wu J-K, Koong AC, Chang DT. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Pract Radiat Oncol. 2014;4:198–206.CrossRefPubMed
26.
go back to reference Franco P, Ragona R, Arcadipane F, et al. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Clin Transl Oncol. 2017;19:67–75.CrossRefPubMed Franco P, Ragona R, Arcadipane F, et al. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Clin Transl Oncol. 2017;19:67–75.CrossRefPubMed
27.
go back to reference Wan J, Liu K, Li K, Li G, Zhang Z. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy? Radiat Oncol. 2015;10:162.CrossRefPubMedPubMedCentral Wan J, Liu K, Li K, Li G, Zhang Z. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy? Radiat Oncol. 2015;10:162.CrossRefPubMedPubMedCentral
28.
go back to reference Alongi F, Fersino S, Mazzola R, et al. Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl Oncol. 2017;19:189–96.CrossRefPubMed Alongi F, Fersino S, Mazzola R, et al. Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl Oncol. 2017;19:189–96.CrossRefPubMed
29.
go back to reference Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76:S101–7.CrossRefPubMed Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76:S101–7.CrossRefPubMed
30.
go back to reference Martin J, Fitzpatrick K, Horan G, et al. Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: results of a prospective study. Radiother Oncol. 2005;74:267–74.CrossRefPubMed Martin J, Fitzpatrick K, Horan G, et al. Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: results of a prospective study. Radiother Oncol. 2005;74:267–74.CrossRefPubMed
31.
go back to reference White R, Foroudi F, Sia J, Marr MA, Lim Joon D. Reduced dose to small bowel with the prone position and a belly board versus the supine position in neoadjuvant 3D conformal radiotherapy for rectal adenocarcinoma. J Med Radiat Sci. 2017;64:120–4.CrossRefPubMed White R, Foroudi F, Sia J, Marr MA, Lim Joon D. Reduced dose to small bowel with the prone position and a belly board versus the supine position in neoadjuvant 3D conformal radiotherapy for rectal adenocarcinoma. J Med Radiat Sci. 2017;64:120–4.CrossRefPubMed
32.
go back to reference Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201–7.CrossRefPubMed Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201–7.CrossRefPubMed
33.
go back to reference Joye I, Haustermans K. Clinical target volume delineation for rectal cancer radiation therapy: time for updated guidelines? Int J Radiat Oncol Biol Phys. 2015;91:690–1.CrossRefPubMed Joye I, Haustermans K. Clinical target volume delineation for rectal cancer radiation therapy: time for updated guidelines? Int J Radiat Oncol Biol Phys. 2015;91:690–1.CrossRefPubMed
35.
go back to reference Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.CrossRefPubMedPubMedCentral Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.CrossRefPubMedPubMedCentral
36.
go back to reference Kusters M, Marijnen CAM, van de Velde CJH, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36:470–6.CrossRefPubMed Kusters M, Marijnen CAM, van de Velde CJH, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36:470–6.CrossRefPubMed
Metadata
Title
Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer
Authors
Hendrik Dapper
Markus Oechsner
Stefan Münch
Kai Borm
Jan Peeken
Michael Mayinger
Stephanie E. Combs
Daniel Habermehl
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-1120-0

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue